

# AUSTRALIAN PRODUCT INFORMATION – ALDACTONE® (SPIRONOLACTONE)

## 1. NAME OF THE MEDICINE

Spironolactone

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

The 25 mg ALDACTONE tablets contain 25 mg spironolactone.

The 100 mg ALDACTONE tablets contain 100 mg spironolactone.

For the full list of excipients, see Section 6.1 List of excipients.

## 3. PHARMACEUTICAL FORM

Film-coated tablets.

25 mg ALDACTONE tablets: 8.7 mm in diameter, round, biconvex, buff coloured, peppermint flavoured, film coated, stamped SEARLE over 39 on one side and unmarked on the other.

100 mg ALDACTONE tablets: 11.2 mm in diameter, round, biconvex, buff coloured, peppermint flavoured, film coated, stamped SEARLE over 134 on one side and unmarked on the other.

## 4. CLINICAL PARTICULARS

### 4.1 Therapeutic indications

#### *Essential Hypertension*

ALDACTONE, when used alone, is effective in lowering both systolic and diastolic blood pressure. ALDACTONE improves the hypotensive action of thiazide diuretics while at the same time reducing or preventing potassium loss due to the thiazide. ALDACTONE enhances the effectiveness of other antihypertensive agents such as beta blockers, vasodilators, etc.

**As adjunctive therapy in malignant hypertension.**

**In diuretic induced hypokalaemia when other measures are considered inappropriate or inadequate.**

**Prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate.**

**Oedematous disorders, such as oedema and ascites of congestive cardiac failure, cirrhosis of the liver, nephrotic syndrome.**

### ***Congestive Cardiac Failure***

ALDACTONE, when used alone, is effective in the management of oedema and sodium retention associated with congestive cardiac failure. ALDACTONE may be used in combination with a thiazide or other conventional diuretics for achieving diuresis in patients whose oedema is resistant to a thiazide or other conventional diuretics. Unlike conventional diuretics ALDACTONE does not produce hypokalaemia. When administered with a thiazide or other conventional diuretics, ALDACTONE offsets hypokalaemia induced by these diuretics. The prevention of potassium loss is particularly important in the treatment of digitalised patients since digitalis intoxication may be precipitated if hypokalaemia is induced by conventional diuretic therapy.

### ***Hepatic Cirrhosis with Ascites and Oedema***

ALDACTONE when used alone is frequently adequate for the relief of ascites and oedema associated with hepatic cirrhosis. ALDACTONE provides a mild and even diuresis and prevents excessive potassium excretion caused by thiazide diuretics thus avoiding possible precipitation of hepatic coma.

### ***Nephrotic Syndrome***

Although glucocorticoids, whose anti-inflammatory activity appears to benefit the primary pathologic process in the renal glomerulus, should probably be employed first, ALDACTONE either alone or in combination with a conventional diuretic is useful for inducing diuresis.

### ***Diagnosis and treatment of primary hyperaldosteronism***

ALDACTONE may be used to establish the diagnosis of primary hyperaldosteronism by therapeutic trial. ALDACTONE may also be used for the short term pre-operative treatment of patients with primary hyperaldosteronism, long term maintenance therapy for patients with discrete aldosterone producing adrenal adenomas who are judged to be poor operative risks (or who decline surgery), and the long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism).

### ***Hirsutism***

ALDACTONE is effective in the treatment of females with hirsutism, an androgen related increase in facial and body hair. A reduction in hair growth, hair shaft diameter and hair pigmentation are seen.

Use of ALDACTONE should be considered only after all other alternatives of non-drug therapy has been explored. For women of child bearing age, see section 4.3 Contraindications and section 4.6 Fertility, pregnancy and use in lactation: Use in pregnancy.

## **4.2 Dose and method of administration**

### **Dosage**

#### ***Adults***

### **Essential Hypertension**

50 mg/day to 100 mg/day which may be given either in divided doses or as a single daily dose.

Dosage should be adjusted according to response, but it should be noted that maximum effect of ALDACTONE therapy may not occur for up to 2 weeks after starting treatment.

ALDACTONE may potentiate the action of diuretics or other antihypertensive drugs and their dosage should first be reduced by at least 50% when ALDACTONE is added to the regimen, and then adjusted as necessary.

### **Oedematous Disorders**

The daily dose may be given either in divided doses or as a single daily dose.

Congestive Cardiac Failure: Initial dose: 100 mg/day. In difficult or severe cases, the dosage may be gradually increased up to 200 mg/day. When oedema is controlled, the usual maintenance level is 25 mg/day to 200 mg/day.

Cirrhosis: If urinary Na<sup>+</sup>/K<sup>+</sup> ratio is greater than 1 (one) the recommended dose is 100 mg/day. If the ratio is less than 1 (one) the recommended dose is 200 mg/day to 400 mg/day. Maintenance dosage should be individually determined.

Nephrotic Syndrome: Usually 100 mg/day to 200 mg/day. Spironolactone is not anti-inflammatory, has not been shown to affect the basic pathological process, and its use is only advised when treatment of the underlying disease, restriction of fluid intake and sodium intake, and the use of other diuretics do not provide an adequate response.

### **Diagnosis and Treatment of Primary Aldosteronism**

ALDACTONE may be employed as an initial diagnostic measure to provide presumptive evidence of primary hyperaldosteronism while patients are on normal diets.

Long Test: ALDACTONE is administered at a daily dosage of 400 mg for 3 to 4 weeks. Correction of hypokalaemia and hypertension provides presumptive evidence for the diagnosis of primary hyperaldosteronism.

Short Test: ALDACTONE is administered at a daily dosage of 400 mg for 4 days. If serum potassium increases during ALDACTONE administration but drops when ALDACTONE is discontinued, a presumptive diagnosis of primary hyperaldosteronism should be considered.

After the diagnosis of hyperaldosteronism has been established by more definitive testing procedures, ALDACTONE may be administered in doses of 100 mg to 400 mg daily in preparation for surgery. For patients who are considered unsuitable for surgery, ALDACTONE may be employed for long term maintenance therapy at the lowest effective dosage determined for the individual patient.

### **Malignant Hypertension**

ALDACTONE should be used as adjunctive therapy only, where there is an excessive secretion of aldosterone, hypokalaemia and metabolic alkalosis. Initial dosage: 100 mg/day increased as necessary in two weekly intervals to 400 mg/day. Initial therapy should include a combination of other antihypertensive drugs and spironolactone. Do not automatically reduce the dose of other treatments as is recommended for essential hypertension.

## **Hypokalaemia**

ALDACTONE may be useful in treating diuretic induced hypokalaemia when oral potassium supplements are considered inappropriate. In treating hypokalaemia, the lowest dose should be used and titrated upwards. A daily dose exceeding 100 mg is not recommended.

## **Female Hirsutism**

100 mg/day to 200 mg/day in divided doses is usual however 50 mg/day has also been shown to be effective.

Clinical improvement is usually shown within 3 to 6 months and an initial course of treatment should continue for 12 months.

ALDACTONE may be administered continuously or as a cyclical dosage for approximately 3 weeks out of every 4 weeks. Dosing from Day 5 to Day 21 of the menstrual cycle, with a drug free interval during menstruation has been effective.

Cyclical dosing may reduce menstrual irregularities in women with previously regular cycles.

Combined use with oestrogen progestogen oral contraceptives may also be considered to provide both regular menstrual cycles and adequate contraception (see section 4.6 Fertility, pregnancy and use in lactation: Use in pregnancy).

## ***Children and Adolescents***

### **Oedema**

The initial daily dosage should provide approximately 3.3 mg/kg. For small children, ALDACTONE tablets may be pulverised and administered as a suspension in cherry syrup. When refrigerated, such a suspension is stable for 1 month.

## **4.3 Contraindications**

Acute renal insufficiency, significant impairment of renal function, anuria.

Addison's disease or other conditions associated with hyperkalaemia (see section 4.4 Special warnings and precautions for use).

Hyperkalaemia.

Pregnancy.

Hypersensitivity to spironolactone.

Concomitant use of eplerenone.

## **4.4 Special warnings and precautions for use**

Concomitant use of spironolactone with angiotensin converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs, angiotensin II antagonists, aldosterone blockers, heparin, low molecular weight heparin, other drugs or conditions known to cause

hyperkalaemia, potassium supplements, a diet rich in potassium, including salt substitutes containing potassium, or other potassium sparing agents is not recommended as it may lead to severe hyperkalaemia.

Hyperkalaemia may be fatal in patients with Severe Heart Failure (New York Heart Association [NYHA] class III-IV). Potassium and creatinine levels should be closely monitored 1 week after initiation or monthly for the first 3 months, then quarterly for a year, and then every 6 months when increasing the dose of spironolactone. Concomitant use of spironolactone and other potassium-sparing diuretics in patients with severe heart failure should be avoided. If serum potassium is  $>3.5$  mEq/L, oral potassium supplements should be avoided. Treatment with spironolactone should be discontinued or interrupted in patients with serum potassium  $>5$  mEq/L or with serum creatinine  $>4$  mg/dL.

Periodic estimation of serum electrolytes is desirable due to the possibility of hyperkalaemia, hyponatraemia and possible transient blood urea nitrogen (BUN) elevation especially in the elderly and/or patients with pre-existing impaired renal or hepatic function, in whom the risk/benefit ratio should always be weighed.

Reversible hyperchloraemic metabolic acidosis, usually in association with hyperkalaemia, has been reported to occur in some patients with decompensated hepatic cirrhosis, even in the presence of normal renal function.

The safety of ALDACTONE for the treatment of hirsutism in women of child bearing age has not been established by specific long-term clinical trials. Epidemiological studies are also inadequate to establish the safety of long-term use in this population.

#### **Use in hepatic impairment**

See section 4.4 Special warnings and precautions for use.

#### **Use in renal impairment**

See section 4.3 Contraindications and section 4.4 Special warnings and precautions for use.

#### **Use in the elderly**

See section 4.4 Special warnings and precautions for use.

#### **Paediatric use**

No data available.

#### **Effects on laboratory tests**

Spironolactone can interfere with assays for plasma digoxin concentrations.

### **4.5 Interactions with other medicines and other forms of interactions**

Concomitant use of drugs known to cause hyperkalaemia with spironolactone may result in severe hyperkalaemia (see section 4.4 Special warnings and precautions for use).

Hyperkalaemia has been associated with the use of indomethacin or ACE inhibitors in combination with potassium sparing diuretics.

Spirolactone reduces the vascular responsiveness to noradrenaline. Therefore, caution should be exercised in the management of patients subjected to regional or general anaesthesia while they are being treated with ALDACTONE.

As carbenoxolone may cause sodium retention and thus decrease the effectiveness of spironolactone, concurrent use of the two agents should be avoided.

Spirolactone has been shown to increase the half-life of digoxin. This may result in increased serum digoxin levels and subsequent digitalis toxicity. It may be necessary to reduce the digoxin dose when spironolactone is administered, and the patient should be carefully monitored to avoid over or under-digitalisation.

Spirolactone may have an additive effect when given concomitantly with other diuretics and antihypertensive agents. The dose of such drugs may need to be reduced when spironolactone is added to the treatment regimen.

Nonsteroidal anti-inflammatory drugs such as aspirin, indomethacin, and mefenamic acid may attenuate the natriuretic efficacy of diuretics due to inhibition of intrarenal synthesis of prostaglandins and have been shown to attenuate the diuretic effect of spironolactone.

Spirolactone enhances the metabolism of antipyrene.

Hyperkalaemic metabolic acidosis has been reported in patients given spironolactone concurrently with ammonium chloride or cholestyramine.

## **4.6 Fertility, pregnancy and lactation**

### **Effects on fertility**

In animal studies, spironolactone was devoid of teratogenic effects in mice and rabbits at oral doses up to 20 mg/kg/day, and in rats at dietary doses up to 50 mg/kg/day. However, increased resorption rate was seen at 20 mg/kg/day in rabbits, and the incidence of stillbirths was increased in rats dosed at 50 mg/kg/day. Subcutaneous administration of spironolactone (approximately 50 mg/kg/day to 100 mg/kg/day) to rats during late pregnancy caused endocrine dysfunction in both sexes of offspring 70-80 days after birth (hypoprolactinaemia and decreased ventral prostate and seminal vesicle weights in males; increased luteinizing hormone secretion and ovarian and uterine weights in females). Feminisation of the external genitalia of male fetuses was reported in another study in rats at oral doses of approximately 200 mg/kg/day. Subcutaneous administration of spironolactone to neonatal female mice caused histological changes in the cervicovaginal epithelium that were similar to those caused by diethylstilboestrol (a drug which causes vaginal neoplasia in adulthood following in utero exposure).

The risk of demasculinisation of the male fetus will only occur from about 6 weeks post conception onwards, hence if inadvertent spironolactone administration is stopped at an early stage the risk to the male fetus is small.

### **Use in pregnancy – Pregnancy Category B3**

Experimentally, passive transfer of potassium sparing diuretics across the human placenta has been demonstrated. Maternal treatment during pregnancy may result in electrolyte disturbances in the fetus. Spirolactone should not be used in pregnancy (see 4.3

Contraindications). Women of child-bearing potential should employ adequate contraception (i.e. oral contraceptives or IUDs) during administration of spironolactone, and the drug should be stopped if pregnancy occurs or is suspected.

### **Use in lactation**

Canrenone, an active metabolite of spironolactone, appears in breast milk. If use of the drug is deemed essential an alternative method of infant feeding should be instituted.

## **4.7 Effects on ability to drive and use machines**

Somnolence and dizziness have been reported to occur in some patients. Caution is advised when driving or operating machinery until the response to initial treatment has been determined.

## **4.8 Adverse effects (undesirable effects)**

Gynaecomastia may develop in association with the use of spironolactone, and physicians should be alert to its possible onset. The development of gynaecomastia appears to be related to both dosage level and duration of therapy and is normally reversible when ALDACTONE is discontinued. In rare instances some breast enlargement may persist.

Other adverse reactions that have been reported in association with ALDACTONE are: gastrointestinal symptoms including cramping, diarrhoea, nausea, vomiting, gastric bleeding, ulceration and gastritis; drowsiness, lethargy, headache, maculopapular or erythematous cutaneous eruptions, urticaria, mental confusion, drug fever, ataxia, inability to achieve or maintain erection, irregular menses or amenorrhoea, post-menopausal bleeding, malaise, benign breast neoplasm, breast pain, leucopenia (including agranulocytosis), thrombocytopenia, abnormal hepatic function, electrolyte disturbances, hyperkalaemia, leg cramps dizziness, changes in libido, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS), alopecia, hypertrichosis, pruritus, rash, and acute renal failure.

Carcinoma of the breast has been reported in patients taking spironolactone, but a cause and effect relationship has not been established.

### **Reporting suspected adverse effects**

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at [www.tga.gov.au/reporting-problems](http://www.tga.gov.au/reporting-problems).

## **4.9 Overdose**

### **Symptoms**

Overdosage may be manifested by nausea and vomiting, dizziness and (more rarely) by drowsiness, mental confusion, maculopapular or erythematous rash or diarrhoea. Electrolyte imbalances and dehydration may occur. Hyperkalaemia may be produced; symptoms include paraesthesia, weakness, flaccid paralysis and tetany. The earliest signs are characteristic

electrocardiographic abnormalities including tall "tent shaped" T waves, decreased amplitude of the P waves and widening of the QRS complex. Delayed onset of hyperkalaemia has been reported after acute ingestion of spironolactone (peak levels at 24 hours and 32 hours).

## **Treatments**

Symptomatic and supportive measures should be employed. There is no specific antidote. Support respiratory and cardiac functions. Treat fluid depletion, electrolyte imbalances, and hypotension by established procedures.

Severity of intoxication should be based on clinical findings and serial determination of serum potassium levels. Monitoring plasma levels of spironolactone is not clinically useful.

Hyperkalaemia can be treated promptly by the rapid intravenous administration of glucose (20% to 50%) and regular insulin, using 0.25 to 0.5 units of insulin per gram of glucose. Potassium excreting diuretics and ion exchange resins may also be administered repeating as required.

ALDACTONE should be discontinued and potassium intake (including dietary potassium) restricted.

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

#### **Mechanism of action**

ALDACTONE (spironolactone) is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors at the aldosterone dependent sodium potassium exchange site in the distal convoluted renal tubule. ALDACTONE causes increased amounts of sodium and water to be excreted, while potassium is retained. ALDACTONE acts both as a diuretic and as an antihypertensive agent. It may be given alone or with other diuretic agents that act more proximally in the renal tubule.

Increased levels of the mineralocorticoid, aldosterone, are present in primary and secondary hyperaldosteronism. Oedematous states in which secondary aldosteronism is usually involved include congestive cardiac failure, hepatic cirrhosis, and nephrotic syndrome. By competing with aldosterone for receptor sites, ALDACTONE provides effective therapy for oedema and ascites in those conditions.

ALDACTONE is effective in lowering the systolic and diastolic blood pressure in patients with primary hyperaldosteronism. It is also effective in most cases of essential hypertension despite the fact that aldosterone secretion may be within normal limits in benign essential hypertension.

Through its action in antagonising the effect of aldosterone, ALDACTONE inhibits the exchange of sodium for potassium in the distal renal tubule and helps to prevent potassium loss.

ALDACTONE has not been demonstrated to elevate serum uric acid, to precipitate gout or to alter carbohydrate metabolism.

ALDACTONE has moderate anti androgenic activity in humans by inhibition of the interaction between dihydrotestosterone and the intracellular androgen receptor. It also inhibits several steps in ovarian steroidogenesis resulting in lowered plasma levels of testosterone and some other weak androgenic steroids. Through this activity ALDACTONE is effective in the treatment of female hirsutism.

### **Clinical trials**

No data available.

## **5.2 Pharmacokinetic properties**

### **Absorption**

In the human, the bioavailability of spironolactone from orally administered ALDACTONE tablets exceeds 90% when compared with an optimally absorbed solution (spironolactone in polyethylene glycol 400).

Food may increase the bioavailability of spironolactone the clinical relevance of this effect is uncertain.

### **Metabolism**

Spironolactone is rapidly and extensively metabolised.

Approximately 25% to 30% of the dose administered is converted to canrenone. Sulfur containing products are the predominant metabolites and together with spironolactone are thought to be primarily responsible for the therapeutic effects of the drug. Canrenone attains peak serum levels at two to four hours following single oral administration. Canrenone plasma concentrations decline in two distinct phases, being rapid in the first 12 hours and slower from 12 to 96 hours. The log linear phase half-life of canrenone, following multiple doses of ALDACTONE, is between 13 and 24 hours. Both spironolactone and canrenone are more than 90% bound to plasma proteins.

### **Excretion**

The metabolites of spironolactone are excreted primarily in urine, but also in bile.

## **5.3 Preclinical safety data**

### **Genotoxicity**

See section 5.3 Preclinical safety data: Carcinogenicity.

### **Carcinogenicity**

Spironolactone has been shown to be tumorigenic in chronic toxicity studies performed in rats. It should be used only for approved indications. Unnecessary use of this drug should be avoided.

In chronic toxicity studies of spironolactone in rats, changes were observed in the endocrine organs, and the liver. In one study using dietary doses of 50 mg/kg/day, 150 mg/kg/day and 500 mg/kg/day there was a statistically significant dose related increase in benign adenomas of thyroid follicular cells and testicular interstitial cells. In female rats there was a statistically significant increase in malignant mammary tumours at the mid dose only. In male rats there was a dose related increase in proliferative changes in the liver, which included hyperplastic nodules and hepatocellular carcinomas at the mid and high doses.

In a 2-year oral carcinogenicity study in which rats were administered 10 mg/kg/day, 30 mg/kg/day, 100 mg/kg/day, and 150 mg/kg/day of spironolactone, the range of proliferative effects observed was consistent with earlier studies. There were statistically significant increases at the higher doses in hepatocellular adenomas and testicular interstitial cell tumours in males, and in thyroid follicular cell adenomas and carcinomas in both sexes. There was also a statistically significant increase in benign uterine endometrial polyps in females. There was an increase in hepatocellular carcinomas in males at 150 mg/kg but this was not statistically significant. There was no significant increase in the incidence of mammary tumours.

The significance of these findings with respect to clinical use is not known.

Spironolactone was not mutagenic in the Ames test using five strains of *Salmonella typhimurium* with or without metabolic activation.

A dose-related (above 20 mg/kg/day) incidence of myelocytic leukaemia was observed in rats fed daily doses of potassium canrenoate for a period of 1 year. Canrenone and canrenoic acid are the major metabolites of potassium canrenoate. Spironolactone is also metabolised to canrenone. In long-term (2 year) oral carcinogenicity studies of potassium canrenoate in rats, myelocytic leukaemia and hepatic, thyroid, testicular and mammary tumours were observed. Potassium canrenoate did not produce a mutagenic effect in tests using bacteria or yeast. It did produce a positive mutagenic effect in several *in vitro* tests in mammalian cells following metabolic activation. In an *in vivo* mammalian system potassium canrenoate was not mutagenic. An increased incidence of leukaemia was not observed in chronic rat toxicity or carcinogenicity studies conducted with spironolactone at doses up to 500 mg/kg/day. The recommended human dose of spironolactone is 1.4 mg/kg/day to 5.7 mg/kg/day.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

calcium sulfate dihydrate  
maize starch  
povidone  
magnesium stearate  
hypromellose  
macrogol 400  
Felcofix peppermint flavour 961149/701213  
Opaspray yellow M-1-6032B

## 6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

## 6.3 Shelf life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

## 6.4 Special precautions for storage

Store below 30°C.

## 6.5 Nature and contents of container


The 25 mg and 100 mg tablets are available as blister packs of 100 tablets.

## 6.6 Special precautions for disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

## 6.7 Physicochemical properties

### Chemical structure



### CAS number

52-01-7

## 7. MEDICINE SCHEDULE (POISONS STANDARD)

Prescription Only Medicine (S4).

## 8. SPONSOR

Pfizer Australia Pty Ltd  
Level 17, 151 Clarence Street  
Sydney NSW 2000  
Toll Free Number: 1800 675 229  
[www.pfizer.com.au](http://www.pfizer.com.au)

## 9. DATE OF FIRST APPROVAL

28 May 1999.

## 10. DATE OF REVISION

27 February 2020

®Registered trademark.

### Summary Table of Changes

Section changed	Summary of new information
All	All sections reformatted in line with the new form.
3	Addition of pharmaceutical form description.
6.1, 6.4, 6.5, 6.7	Addition of list of excipients, precautions for storage, pack type, chemical structure and CAS number in line with the new form.
8	Update sponsor address.